Gilead Sciences, Inc. cash flow to debt ratio of 40.74% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Gilead Sciences, Inc.'s free cash flow has decreased -8.24% from $10.30G last year to $9.46G, signaling decreasing performance

Gilead Sciences, Inc.'s debt to equity ratio is 0.94, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Gilead Sciences, Inc.'s debt has decreased relative to shareholder equity from 1.38 last year to 0.94 today, signaling strengthened financials

Gilead Sciences, Inc. has a net debt to EBITDA ratio of 1.25x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Gilead Sciences, Inc.'s interest coverage ratio of 11.32 indicates that earnings with good margin can cover interest payments on company debt

Gilead Sciences, Inc.'s profit margin has increased (1.76K%) in the last year from 1.67% to 30.99%, signaling increasing performance

Gilead Sciences, Inc.'s short-term assets of $19.89G exceed its short-term liabilities of $11.81G

Gilead Sciences, Inc.'s return on assets of 16.38% is higher than the 5.00% threshold, indicating efficient asset utilization

Gilead Sciences, Inc.'s return on equity of 42.16%, is higher than 15.00%, indicating good performance

Gilead Sciences, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Gilead Sciences, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Gilead Sciences, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Gilead Sciences, Inc. has a free cash flow yield of 5.96%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Gilead Sciences, Inc.'s yearly earnings has increased 1.67K% since last year from $480.00M to $8.51G, signaling increasing performance

Gilead Sciences, Inc.'s yearly revenue has increased 2.40% since last year from $28.75G to $29.44G, signaling increasing performance

ROIC 20.31% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Gilead Sciences, Inc.'s 3-year revenue CAGR of 2.57% is positive, indicating growing revenue over the past 3 years

Gilead Sciences, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Gilead Sciences, Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Gilead Sciences, Inc. is overvalued relative to its fair value price of 95.07 based on Discounted Cash Flow model

Gilead Sciences, Inc. has an earnings yield of 5.80%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Gilead Sciences, Inc. is overvalued relative to its fair value price of 47.31 based on EBITDA multiple model

Gilead Sciences, Inc. has an EV/EBITDA ratio of 12.36x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Gilead Sciences, Inc. is overvalued relative to its fair value price of 86.19 based on Earnings Fair Value model

Gilead Sciences, Inc. has a PEG-ratio under 1 which is considered undervalued

Gilead Sciences, Inc. has a price-to-book ratio of 6.75x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Gilead Sciences, Inc. has a price-to-sales ratio of 5.34x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue